Bal Pharma Limited (NSE:BALPHARMA)

Bal Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	87.23	17.52	41.96	14.87	11.13	10.23
Short-Term Investments	4.02	86.59	157.33	59.76	47.3	29.48
Cash & Short-Term Investments	91.26	104.1	199.29	74.63	58.43	39.71
Cash Growth	-63.08%	-47.76%	167.05%	27.72%	47.14%	13.24%
Accounts Receivable	908.24	924.44	996.22	939.76	753.12	671.97
Other Receivables	-	31.07	32.81	27.56	51.87	42.99
Receivables	920.14	966.83	1,043	976.92	828.67	735.6
Inventory	1,127	1,030	878.11	980.05	743.96	603.85
Prepaid Expenses	-	13.44	9.69	7.2	5.86	0.8
Other Current Assets	311.78	234.13	211.66	242.77	208.79	261.51
Total Current Assets	2,450	2,349	2,342	2,282	1,846	1,641
Property, Plant & Equipment	792.06	737.76	647.89	621.79	571.85	575.09
Long-Term Investments	-	42.35	2.81	13.98	18.09	23.86
Goodwill	38.27	38.27	38.27	38.29	38.29	38.29
Other Intangible Assets	124.66	9.79	12.49	13.16	2.09	0.59
Long-Term Deferred Tax Assets	4.1	4.1	-	21.67	-	-
Long-Term Deferred Charges	-	110.18	101.32	91.41	77.83	71.89
Other Long-Term Assets	84.53	65.73	52.82	48.9	47.53	45.78
Total Assets	3,494	3,357	3,198	3,132	2,605	2,401
Accounts Payable	842.04	816.86	774.64	789.23	655.64	471.67
Accrued Expenses	11.64	73.14	37.77	34.69	70.82	58.64
Short-Term Debt	-	1,073	957.61	927.17	707.49	821.21
Current Portion of Long-Term Debt	1,235	116.7	74.88	77.6	58.79	52.72
Current Portion of Leases	-	6.38	12.77	8.55	7.62	3.08
Current Income Taxes Payable	-	-	22.18	60.06	43.93	6.14
Other Current Liabilities	200.17	108.83	150.72	196.06	112.17	111.88
Total Current Liabilities	2,289	2,195	2,031	2,093	1,656	1,525
Long-Term Debt	313.67	314	363.49	305.23	270.14	239.32
Long-Term Leases	-	12.9	13.74	12.25	22.54	16.15
Pension & Post-Retirement Benefits	-	47.32	42.62	42.38	39.82	35.42
Long-Term Deferred Tax Liabilities	-	-	15.49	28.69	6.04	26.32
Other Long-Term Liabilities	107.77	13.64	12.75	12.8	25.42	24.72
Total Liabilities	2,710	2,583	2,479	2,495	2,020	1,867
Common Stock	159.21	159.21	158.04	156.9	148.22	148.22
Additional Paid-In Capital	-	319.78	312.87	301.84	266.77	266.77
Retained Earnings	-	297.62	245.04	171.4	160.33	119.03
Comprehensive Income & Other	624.05	-2.45	4.09	7.75	10.95	1.79
Total Common Equity	783.26	774.16	720.04	637.89	586.27	535.82
Minority Interest	0.04	-0.12	-0.33	-0.87	-1.34	-2.28
Shareholders' Equity	783.3	774.04	719.72	637.02	584.92	533.54
Total Liabilities & Equity	3,494	3,357	3,198	3,132	2,605	2,401
Total Debt	1,549	1,523	1,423	1,331	1,067	1,132
Net Cash (Debt)	-1,458	-1,419	-1,223	-1,256	-1,008	-1,093
Net Cash Per Share	-91.64	-89.51	-77.73	-80.06	-68.02	-76.96
Filing Date Shares Outstanding	15.77	15.92	15.8	15.69	15.57	14.82
Total Common Shares Outstanding	15.77	15.92	15.8	15.69	14.82	14.82
Working Capital	161.13	153.72	311.04	188.22	189.26	116.15
Book Value Per Share	49.68	48.63	45.56	40.66	39.55	36.15
Tangible Book Value	620.34	726.1	669.28	586.45	545.89	496.94
Tangible Book Value Per Share	39.34	45.61	42.35	37.38	36.83	33.53
Land	-	172.71	148.93	148.93	79.1	79.1
Buildings	-	239.38	233.21	222.2	214.15	208.79
Machinery	-	763.63	671.8	613.08	558.05	539.09
Construction In Progress	-	27.86	4.72	-	16.12	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.